

# Maria Paola Castelli

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8736300/publications.pdf>

Version: 2024-02-01

61  
papers

1,970  
citations

185998

28  
h-index

253896

43  
g-index

61  
all docs

61  
docs citations

61  
times ranked

2483  
citing authors

#	ARTICLE	IF	CITATIONS
1	COR758, a negative allosteric modulator of GABAB receptors. <i>Neuropharmacology</i> , 2021, 189, 108537.	2.0	6
2	Repeated exposure to JWH018 induces adaptive changes in the mesolimbic and mesocortical dopaminergic pathways, glial cells alterations, and behavioural correlates. <i>British Journal of Pharmacology</i> , 2021, 178, 3476-3497.	2.7	12
3	Human Neuronal Cell Lines as An In Vitro Toxicological Tool for the Evaluation of Novel Psychoactive Substances. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6785.	1.8	8
4	The GABAB receptor positive allosteric modulator COR659: In vitro metabolism, in vivo pharmacokinetics in rats, synthesis and pharmacological characterization of metabolically protected derivatives. <i>European Journal of Pharmaceutical Sciences</i> , 2020, 155, 105544.	1.9	9
5	Structure optimization of positive allosteric modulators of GABAB receptors led to the unexpected discovery of antagonists/potential negative allosteric modulators. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 127443.	1.0	0
6	Sex and Gender Differences in the Effects of Novel Psychoactive Substances. <i>Brain Sciences</i> , 2020, 10, 606.	1.1	28
7	Predisposition to Alcohol Drinking and Alcohol Consumption Alter Expression of Calcitonin Gene-Related Peptide, Neuropeptide Y, and Microglia in Bed Nucleus of Stria Terminalis in a Subnucleus-Specific Manner. <i>Frontiers in Cellular Neuroscience</i> , 2019, 13, 158.	1.8	7
8	Neurochemical and Behavioral Profiling in Male and Female Rats of the Psychedelic Agent 25I-NBOMe. <i>Frontiers in Pharmacology</i> , 2019, 10, 1406.	1.6	25
9	Impaired brain endocannabinoid tone in the activity-based model of anorexia nervosa. <i>International Journal of Eating Disorders</i> , 2019, 52, 1251-1262.	2.1	19
10	Rimonabant, a potent CB1 cannabinoid receptor antagonist, is a G $\pm$ i/o protein inhibitor. <i>Neuropharmacology</i> , 2018, 133, 107-120.	2.0	21
11	In Vitro Functional Characterization of GET73 as Possible Negative Allosteric Modulator of Metabotropic Glutamate Receptor 5. <i>Frontiers in Pharmacology</i> , 2018, 9, 327.	1.6	6
12	Limited Access to a High Fat Diet Alters Endocannabinoid Tone in Female Rats. <i>Frontiers in Neuroscience</i> , 2018, 12, 40.	1.4	19
13	Suppressing effect of saikosaponin A, an active ingredient of <i>Bupleurum falcatum</i> , on chocolate self-administration and reinstatement of chocolate seeking in rats. <i>Neuroscience Letters</i> , 2017, 638, 211-217.	1.0	11
14	Cannabis and the Use of Amphetamine-Like Substances. , 2017, , e101-e110.		1
15	Influence of caffeine on 3,4-methylenedioxymethamphetamine-induced dopaminergic neuron degeneration and neuroinflammation is age-dependent. <i>Journal of Neurochemistry</i> , 2016, 136, 148-162.	2.1	31
16	Distribution and Localization of the GABAB Receptor. , 2016, , 75-92.		6
17	$\beta$ 2A adrenergic receptors highly expressed in mesoprefrontal dopamine neurons. <i>Neuroscience</i> , 2016, 332, 130-139.	1.1	13
18	In vitro and in vivo pharmacological characterization of SSD114, a novel GABAB positive allosteric modulator. <i>European Journal of Pharmacology</i> , 2016, 791, 115-123.	1.7	6

#	ARTICLE	IF	CITATIONS
19	Native CB1 receptor affinity, intrinsic activity and accumbens shell dopamine stimulant properties of third generation SPICE/K2 cannabinoids: BB-22, 5F-PB-22, 5F-AKB-48 and STS-135. <i>Neuropharmacology</i> , 2016, 105, 630-638.	2.0	67
20	Enhanced Endocannabinoid-Mediated Modulation of Rostromedial Tegmental Nucleus Drive onto Dopamine Neurons in Sardinian Alcohol-Preferring Rats. <i>Journal of Neuroscience</i> , 2014, 34, 12716-12724.	1.7	47
21	Synthesis, structural properties, and pharmacological evaluation of 2-(acylamino)thiophene-3-carboxamides and analogues thereof. <i>RSC Advances</i> , 2014, 4, 1782-1793.	1.7	5
22	The aggression and behavioral abnormalities associated with monoamine oxidase A deficiency are rescued by acute inhibition of serotonin reuptake. <i>Journal of Psychiatric Research</i> , 2014, 56, 1-9.	1.5	33
23	Δ <sup>9</sup> -Tetrahydrocannabinol Prevents Methamphetamine-Induced Neurotoxicity. <i>PLoS ONE</i> , 2014, 9, e98079.	1.1	22
24	The Role of the Endocannabinoid System in Eating Disorders: Neurochemical and Behavioural Preclinical Evidence. <i>Current Pharmaceutical Design</i> , 2014, 20, 2089-2099.	0.9	30
25	Male and Female Rats Differ in Brain Cannabinoid CB1 Receptor Density and Function and in Behavioural Traits Predisposing to Drug Addiction: Effect of Ovarian Hormones. <i>Current Pharmaceutical Design</i> , 2014, 20, 2100-2113.	0.9	108
26	Regional distribution of 5α-reductase type 2 in the adult rat brain: An immunohistochemical analysis. <i>Psychoneuroendocrinology</i> , 2013, 38, 281-293.	1.3	62
27	Synthesis and Pharmacological Characterization of 2-(Acylamino)thiophene Derivatives as Metabolically Stable, Orally Effective, Positive Allosteric Modulators of the GABA <sub>B</sub> Receptor. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 3620-3635.	2.9	33
28	PPAR $\delta$ Regulates Cholinergic-Driven Activity of Midbrain Dopamine Neurons via a Novel Mechanism Involving $\alpha$ 7 Nicotinic Acetylcholine Receptors. <i>Journal of Neuroscience</i> , 2013, 33, 6203-6211.	1.7	79
29	The New Compound GET73, N-[(4-trifluoromethyl)benzyl]4-methoxybutyramide, Regulates Hippocampal Aminoacidergic Transmission Possibly Via an Allosteric Modulation of mGlu5 Receptor. Behavioural Evidence of its Anti-Alcohol and Anxiolytic Properties. <i>Current Medicinal Chemistry</i> , 2013, 20, 3339-3357.	1.2	15
30	Characterization of COR627 and COR628, Two Novel Positive Allosteric Modulators of the GABA <sub>B</sub> Receptor. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2012, 340, 529-538.	1.3	38
31	NMDARs Mediate the Role of Monoamine Oxidase A in Pathological Aggression. <i>Journal of Neuroscience</i> , 2012, 32, 8574-8582.	1.7	47
32	Anti-Alcohol and Anxiolytic Properties of a New Chemical Entity, GET73. <i>Frontiers in Psychiatry</i> , 2012, 3, 8.	1.3	25
33	Reversible Disruption of Pre-Pulse Inhibition in Hypomorphic-Inducible and Reversible CB1 <sup>-/-</sup> Mice. <i>PLoS ONE</i> , 2012, 7, e35013.	1.1	8
34	Adolescent exposure to nicotine and/or the cannabinoid agonist CP 55,940 induces gender-dependent long-lasting memory impairments and changes in brain nicotinic and CB <sub>1</sub> cannabinoid receptors. <i>Journal of Psychopharmacology</i> , 2011, 25, 1676-1690.	2.0	97
35	Effects of Drugs of Abuse on Putative Rostromedial Tegmental Neurons, Inhibitory Afferents to Midbrain Dopamine Cells. <i>Neuropsychopharmacology</i> , 2011, 36, 589-602.	2.8	135
36	Methamphetamine neurotoxicity increases brain expression and alters behavioral functions of CB1 cannabinoid receptors. <i>Journal of Psychiatric Research</i> , 2010, 44, 944-955.	1.5	18

#	ARTICLE	IF	CITATIONS
37	Methamphetamine Induces Long-Term Alterations in Reactivity to Environmental Stimuli: Correlation with Dopaminergic and Serotonergic Toxicity. <i>Neurotoxicity Research</i> , 2009, 15, 232-245.	1.3	17
38	6 $\alpha$ -Hydroxydopamine lesion in the ventral tegmental area fails to reduce extracellular dopamine in the cerebral cortex. <i>Journal of Neuroscience Research</i> , 2008, 86, 1647-1658.	1.3	25
39	Multi-Faceted Aspects of Gamma-Hydroxybutyric Acid: A Neurotransmitter, Therapeutic Agent and Drug of Abuse. <i>Mini-Reviews in Medicinal Chemistry</i> , 2008, 8, 1188-1202.	1.1	22
40	Cannabinoid CB1 receptors in the paraventricular nucleus and central control of penile erection: Immunocytochemistry, autoradiography and behavioral studies. <i>Neuroscience</i> , 2007, 147, 197-206.	1.1	37
41	Dysregulation of the endogenous cannabinoid system in adult rats prenatally treated with the cannabinoid agonist WIN 55,212-2. <i>European Journal of Pharmacology</i> , 2007, 573, 11-19.	1.7	32
42	Activation of GABAB receptors reverses spontaneous gating deficits in juvenile DBA/2J mice. <i>Psychopharmacology</i> , 2007, 194, 361-369.	1.5	43
43	Design, Synthesis, and Biological Evaluation of New 1,8-Naphthyridin-4(1H)-on-3-carboxamide and Quinolin-4(1H)-on-3-carboxamide Derivatives as CB2 Selective Agonists. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 5947-5957.	2.9	66
44	The cannabinoid receptor antagonist SR-141716A induces penile erection in male rats: Involvement of paraventricular glutamic acid and nitric oxide. <i>Neuropharmacology</i> , 2006, 50, 219-228.	2.0	39
45	Dopamine D3 receptor antisense oligodeoxynucleotide potentiates imipramine-induced dopaminergic behavioural supersensitivity. <i>Behavioural Pharmacology</i> , 2006, 17, 101-106.	0.8	4
46	Up-regulation of GABAB receptors by chronic administration of the GABAB receptor antagonist SCH 50,911. <i>European Journal of Pharmacology</i> , 2005, 515, 94-98.	1.7	11
47	Differential G-protein coupling to GABAB receptor in limbic areas of alcohol-preferring and -nonpreferring rats. <i>European Journal of Pharmacology</i> , 2005, 523, 67-70.	1.7	10
48	A Review of Pharmacology of NCS-382, a Putative Antagonist of $\gamma$ -Hydroxybutyric Acid (GHB) Receptor. <i>CNS Neuroscience &amp; Therapeutics</i> , 2004, 10, 243-260.	4.0	35
49	Selective $\gamma$ -hydroxybutyric acid receptor ligands increase extracellular glutamate in the hippocampus, but fail to activate G protein and to produce the sedative/hypnotic effect of $\gamma$ -hydroxybutyric acid. <i>Journal of Neurochemistry</i> , 2003, 87, 722-732.	2.1	65
50	Central effects of 1,4-butanediol are mediated by GABAB receptors via its conversion into $\gamma$ -hydroxybutyric acid. <i>European Journal of Pharmacology</i> , 2002, 441, 157-163.	1.7	56
51	Stereoselectivity of NCS-382 binding to $\gamma$ -hydroxybutyrate receptor in the rat brain. <i>European Journal of Pharmacology</i> , 2002, 446, 1-5.	1.7	20
52	( $\alpha$ )S amisulpride binds with high affinity to cloned dopamine D3 and D2 receptors. <i>European Journal of Pharmacology</i> , 2001, 432, 143-147.	1.7	20
53	Quantitative autoradiographic distribution of $\gamma$ -hydroxybutyric acid binding sites in human and monkey brain. <i>Molecular Brain Research</i> , 2000, 78, 91-99.	2.5	57
54	Distribution of GABAB receptor mRNAs in the rat brain and peripheral organs. <i>Life Sciences</i> , 1999, 64, 1321-1328.	2.0	77

#	ARTICLE	IF	CITATIONS
55	Chronic morphine and naltrexone fail to modify $\mu$ -opioid receptor mRNA levels in the rat brain. <i>Molecular Brain Research</i> , 1997, 45, 149-153.	2.5	64
56	Molecular pharmacology of the beta-adrenergic receptor on THP-1 cells. <i>International Journal of Immunopharmacology</i> , 1993, 15, 219-228.	1.1	36
57	Thyroid transcription factor 1 activates the promoter of the thyrotropin receptor gene. <i>Molecular Endocrinology</i> , 1993, 7, 1589-1595.	3.7	67
58	Protective, restorative, and therapeutic properties of recombinant colony-stimulating factors. <i>Blood</i> , 1989, 73, 2093-2103.	0.6	41
59	Effects of antiestrogen and progestin on immune functions in breast cancer patients. <i>Cancer</i> , 1988, 61, 2214-2218.	2.0	19
60	Recombinant cytokines IL-2, IL-1, IFN-G, G-CSF and GM-CSF augment CFU-C activity in normal, cyclophosphamide-treated or irradiated mice as well as reduce the lethality of these myelotoxic agents. <i>International Journal of Immunopharmacology</i> , 1988, 10, 52.	1.1	0
61	Continuous subcutaneous insulin infusion (CSII) in pregnant diabetic patients. <i>Prenatal Diagnosis</i> , 1987, 7, 41-50.	1.1	10